Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 3/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.39 |
| ▸ | RXRA | P19793 | 3/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | IP6K1 | Q92551 | 3/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | SNRNP200 | O75643 | 1/20 | 0.37 |
| ▸ | CBX7 | O95931 | 1/20 | 0.37 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24451648 | 1.00 | IMPDH2 (0.40) | IMPDH2PTPN1NR1H2RXRANR1H3 | |
| SCHEMBL24454023 | 0.89 | IP6K1 (0.40) | NR1H2RXRANR1H3ALDH1A1MEN1 | |
| SCHEMBL24451644 | 0.89 | IP6K1 (0.40) | NR1H2RXRANR1H3ALDH1A1MEN1 | |
| SCHEMBL24380252 | 0.89 | IMPDH2 (0.41) | IMPDH2PTPN1NR1H2RXRANR1H3 | |
| SCHEMBL24446810 | 0.89 | IMPDH2 (0.40) | IMPDH2PTPN1NR1H2RXRANR1H3 | |
| SCHEMBL25756972 | 0.88 | IP6K1 (0.41) | IMPDH2PTPN1NR1H2RXRANR1H3 | |
| SCHEMBL24451647 | 0.86 | BACE1 (0.53) | IMPDH2NR1H2RXRANR1H3BACE1 | |
| SCHEMBL6523576 | 0.86 | BACE1 (0.53) | IMPDH2NR1H2RXRANR1H3BACE1 | |
| SCHEMBL3724868 | 0.86 | BACE1 (0.53) | IMPDH2NR1H2RXRANR1H3BACE1 | |
| SCHEMBL29616653 | 0.86 | BACE1 (0.53) | IMPDH2NR1H2RXRANR1H3BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12540141-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-20230103494-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-04-06 | — | — | US | disclosed |
| US-11384090-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11352363-B1 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| WO-2022109363-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| US-20220162216-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-05-26 | — | — | US | disclosed |
| EP-4001279-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | Enanta Pharmaceuticals, Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384090-B2 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, REN | IMPDH2 184/4885PTPN1 786/4885NR1H2 617/4885 |
| US-20230103494-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, ACE2, REN | IMPDH2 135/4885PTPN1 1188/4885NR1H2 460/4885 |
| US-12540141-B2 | Spiropyrrolidine derived antiviral agents | ACE2, NR3C2, ACE | IMPDH2 1219/4885PTPN1 564/4885NR1H2 87/4885 |
| US-20220162216-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, ACE2, REN | IMPDH2 135/4885PTPN1 1188/4885NR1H2 460/4885 |
| US-11352363-B1 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, REN | IMPDH2 339/4885PTPN1 709/4885NR1H2 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.